Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting

BACKGROUND: A regimen of dual (DAT) vs. triple (TAT) antithrombotic therapy reduces bleeding in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, recent evidence suggests that DAT may be associated with an increased ischemic risk. This raises the qu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cardiol Heart Vasc
Main Authors: Riesinger, Lisa, Strobl, Claudia, Leistner, David M., Gori, Tommaso, Akin, Ibrahim, Mehr, Michael, Kellnar, Antonia, Mahabadi, Amir A., Bogossian, Harilaos, Block, Michael, Edelmann, Frank, Sarafoff, Nikolaus, Sibbing, Dirk, Ince, Hüseyin, Rassaf, Tienush, Mansmann, Ulrich, Mehilli, Julinda, Kääb, Stefan, Hausleiter, Jörg, Massberg, Steffen, Wakili, Reza
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8256176/
https://ncbi.nlm.nih.gov/pubmed/34258380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijcha.2021.100810
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados